Publication date: Dec 01, 2018
DNA vaccines have been extensively studied as preventative and therapeutic interventions for various infectious diseases such as tuberculosis, HIV/AIDS and influenza. Despite promising progresses made, improving the immunogenicity of DNA vaccine remains a technical challenge for clinical development. In this study, we investigated a tuberculosis DNA vaccine BER, which contained a codon-optimized fusion immunogen Ag85B-ESAT-6-Rv2660c for enhanced mammalian cell expression and immunogenicity. BER immunization through in vivo electroporation in BALB/c mice induced surprisingly high frequencies of Ag85B tetramer CD8 T cells in peripheral blood and IFN-γ-secreting CD8 T cells in splenocytes. Meanwhile, the BER vaccine-induced long-lasting T cell immunity protected BALB/c mice from high dose viral challenge using a modified vaccinia virus Tiantan strain expressing mature Ag85B protein (MVTT-m85B) and the virulent M. tb H37Rv aerosol challenge. Since the BER DNA vaccine does not induce anti-vector immunity, the strong immunogenicity and protective efficacy of this novel DNA vaccine warrant its future development for M. tb prevention and immunotherapy to alleviate the global TB burden.
Tang, J., Cai, Y., Liang, J., Tan, Z., Tang, X., Zhang, C., Cheng, L., Zhou, J., Wang, H., Yam, W.C., Chen, X., Wang, H., and Chen, Z. In vivo electroporation of a codon-optimized BER DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge. 03468. 2018 Tuberculosis (Edinb) (113):
Please signin to view all article content and metadata.